Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease
Leukemia, Volume 28, No. 3, Year 2014
Notification
URL copied to clipboard!
Description
The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed 197 adults with Ph+ ALL in first complete remission; 67 patients receiving RIC were matched with 130 receiving myeloablative conditioning (MAC) for age, donor type and HCT year. Over 75% received pre-HCT tyrosine kinase inhibitors (TKIs), mostly imatinib; 39% (RIC) and 49% (MAC) were minimal residual disease (MRD) neg pre-HCT. At a median 4.5 years follow-up, 1-year transplant-related mortality (TRM) was lower in RIC (13%) than MAC (36%; P=0.001) while the 3-year relapse rate was 49% in RIC and 28% in MAC (P=0.058). Overall survival (OS) was similar (RIC 39% (95% confidence interval (CI) 27-52) vs 35% (95% CI 27-44); P=0.62). Patients MRD pos pre-HCT had higher risk of relapse with RIC vs MAC (hazard ratio (HR) 1.97; P=0.026). However, patients receiving pre-HCT TKI in combination with MRD negativity pre-RIC HCT had superior OS (55%) compared with a similar MRD population after MAC (33%; P=0.0042). In multivariate analysis, RIC lowered TRM (HR 0.6; P=0.057), but absence of pre-HCT TKI (HR 1.88; P=0.018), RIC (HR 1.891; P=0.054) and pre-HCT MRD pos (HR 1.6; P=0.070) increased relapse risk. RIC is a valid alternative strategy for Ph+ ALL patients ineligible for MAC and MRD neg status is preferred pre-HCT. © 2014 Macmillan Publishers Limited.
Authors & Co-Authors
Bachanova, V.
United States, Minneapolis
University of Minnesota Medical Center, Fairview
Marks, David Ian
United Kingdom, Bristol
Bristol Royal Hospital for Children
Zhang, Meijie
United States, Milwaukee
Medical College of Wisconsin
Wang, Hailin
United States, Milwaukee
Medical College of Wisconsin
de Lima, Marcos J.G.
United States, Cleveland
University Hospitals Case Medical Center
Aljurf, Mahmoud Deeb
Saudi Arabia, Riyadh
King Faisal Specialist Hospital and Research Centre
Arellano, Martha L.
United States, Atlanta
Emory University
Artz, Andrew S.
United States, Chicago
The University of Chicago Medicine
Bacher, Ulrike
Germany, Hamburg
Universitätsklinikum Hamburg-eppendorf
Cahn, Jean Yves Y.
France, Grenoble
Centre Hospitalier Universitaire de Grenoble
Chen, Yibin A.
United States, Boston
Massachusetts General Hospital
Copelan, Edward A.
United States, Charlotte
Carolinas Healthcare System
Drobyski, William R.
United States, Milwaukee
Medical College of Wisconsin
Gale, Robert Peter
United Kingdom, London
Imperial College London
Gréer, John P.
United States, Nashville
Vanderbilt University Medical Center
Gupta, Vikas A.
Canada, Toronto
Princess Margaret Cancer Centre
Hale, Gregory A.
United States, St Petersburg
All Children's Hospital St. Petersburg
Kebriaei, Partow
United States, Houston
The University of Texas Md Anderson Cancer Center
Lazarus, Hillard Michael
United States, Cleveland
University Hospitals Case Medical Center
Lewis, Ian D.
Australia, Adelaide
Royal Adelaide Hospital
Lewis, Victor Anthony
Canada, Calgary
Alberta Children's Hospital
Liesveld, Jane L.
United States, Rochester
Strong Memorial Hospital
Litzow, Mark Robert
United States, Rochester
Mayo Clinic in Rochester, Minnesota
Loren, Alison Wakoff
United States, Philadelphia
University of Pennsylvania Perelman School of Medicine
Miller, Allan M.
United States, Dallas
Baylor University Medical Center at Dallas
Norkin, Maxim
United States, Gainesville
University of Florida
Oran, Betül M.
United States, Houston
The University of Texas Md Anderson Cancer Center
Pidala, Joseph A.
United States, Tampa
Moffitt Cancer Center
Rowe, Jacob M.
Israel, Haifa
Rambam Health Care Campus Israel
Savani, Bipin N.
United States, Nashville
Vanderbilt University Medical Center
Saber, Wael
United States, Milwaukee
Medical College of Wisconsin
Vij, Ravi A.
United States, St. Louis
Barnes-jewish Hospital
Waller, Edmund K.
United States, Atlanta
Emory University Hospital
Wiernik, Peter H.
United States, New York
Our Lady of Mercy Medical Center
Weisdorf, Daniel J.
United States, Minneapolis
University of Minnesota Medical Center, Fairview
Statistics
Citations: 110
Authors: 35
Affiliations: 28
Identifiers
Doi:
10.1038/leu.2013.253
ISSN:
08876924
e-ISSN:
14765551
Research Areas
Environmental
Study Design
Cross Sectional Study
Cohort Study